Genetics of Plasma soluble Receptor for Advanced Glycation End-products and cardiovascular outcomes in a community-based population: Results from the Atherosclerosis Risk in Communities Study

Nisa M. Maruthur, Man Li, Marc K. Halushka, Brad C. Astor, James S. Pankow, Eric Boerwinkle, Josef Coresh, Elizabeth Selvin, Wen Hong Linda Kao

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Plasma soluble Receptor for Advanced Glycation End-products (sRAGE) is a strong marker of vascular outcomes although evidence on the direction of association is mixed. Compared to whites, blacks have lower levels of sRAGE. We hypothesized that genetic determinants of sRAGE would help clarify the causal role of sRAGE and the black-white difference in sRAGE levels. We conducted a genome-wide analysis of sRAGE in whites and blacks from the Atherosclerosis Risk in Communities Study. Median plasma sRAGE levels were lower in blacks than whites (728 vs. 1067 pg/ml; P<0.0001). The T (vs. C) allele of rs2070600, a missense variant in AGER, the gene encoding RAGE, was associated with approximately 50% lower sRAGE levels in both whites (N = 1,737; P = 7.26x10-16; minor allele frequency (MAF) = 0.04) and blacks (N = 581; P = 0.02; MAF = 0.01). In blacks, the T (vs. C) allele of rs2071288, intronic to AGER, was associated with 43% lower sRAGE levels (P = 2.22x10-8; MAF = 0.10) and was nearly absent in whites. These AGER SNPs explained 21.5% and 26% of the variation in sRAGE in blacks and whites, respectively, but did not explain the black-white difference in sRAGE. These SNPs were not significantly associated with incident death, coronary heart disease, diabetes, heart failure, or chronic kidney disease in whites (N = 8,130-9,017) or blacks (N = 2,293-2,871) (median follow up ∼20 years). We identified strong genetic determinants of sRAGE that did not explain the large black-white difference in sRAGE levels or clearly influence risk of clinical outcomes, suggesting that sRAGE may not be a causal factor in development of these outcomes.

Original languageEnglish (US)
Article numbere0128452
JournalPloS one
Volume10
Issue number6
DOIs
StatePublished - Jun 17 2015

Bibliographical note

Publisher Copyright:
© 2015 Maruthur et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Fingerprint

Dive into the research topics of 'Genetics of Plasma soluble Receptor for Advanced Glycation End-products and cardiovascular outcomes in a community-based population: Results from the Atherosclerosis Risk in Communities Study'. Together they form a unique fingerprint.

Cite this